Data as of Sep 22
| -0.10 / -0.21%|
The 29 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 50.14, with a high estimate of 62.49 and a low estimate of 32.43. The median estimate represents a +3.79% increase from the last price of 48.31.
The current consensus among 30 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.